Adozelesin

Adozelesin
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
UNII
  • InChI=1S/C30H22N4O4/c1-15-13-31-27-22(35)11-25-30(26(15)27)12-18(30)14-34(25)29(37)21-9-17-8-19(6-7-20(17)33-21)32-28(36)24-10-16-4-2-3-5-23(16)38-24/h2-11,13,18,31,33H,12,14H2,1H3,(H,32,36)
    Key: BYRVKDUQDLJUBX-UHFFFAOYSA-N
  • InChI=1/C30H22N4O4/c1-15-13-31-27-22(35)11-25-30(26(15)27)12-18(30)14-34(25)29(37)21-9-17-8-19(6-7-20(17)33-21)32-28(36)24-10-16-4-2-3-5-23(16)38-24/h2-11,13,18,31,33H,12,14H2,1H3,(H,32,36)
    Key: BYRVKDUQDLJUBX-UHFFFAOYAA
  • CC1=CNC2=C1C34CC3CN(C4=CC2=O)C(=O)C5=CC6=C(N5)C=CC(=C6)NC(=O)C7=CC8=CC=CC=C8O7
Properties
C30H22N4O4
Molar mass 502.530 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Adozelesin is an experimental antitumor drug of the duocarmycin class. It binds to and alkylates DNA, resulting in a reduction of both cellular and simian virus 40 (SV40) DNA replication which ultimately reduces the rate of cancer growth.

References

  1. ↑ Wang, Y; Beerman, TA; Kowalski, D (2001). "Antitumor drug adozelesin differentially affects active and silent origins of DNA replication in yeast checkpoint kinase mutants". Cancer Research. 61 (9): 3787–94. PMID 11325853.
  2. ↑ Liu, J.-S.; Kuo, S.-R.; McHugh, M. M.; Beerman, T. A.; Melendy, T. (14 January 2000). "Adozelesin Triggers DNA Damage Response Pathways and Arrests SV40 DNA Replication through Replication Protein A Inactivation". Journal of Biological Chemistry. 275 (2): 1391–1397. doi:10.1074/jbc.275.2.1391. PMID 10625690.